Skip to main content
56°
Mostly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Esperion Therapeutics, Inc. - Common Stock
(NQ:
ESPR
)
0.8928
+0.0028 (+0.31%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 8, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Esperion Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference
Today 8:00 EDT
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 08, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada
May 08, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Earnings Scheduled For May 6, 2025
May 06, 2025
Via
Benzinga
Esperion Reports First Quarter 2025 Financial Results
May 06, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead
May 01, 2025
Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a...
Via
Stocktwits
Topics
Stocks
Exposures
US Equities
Esperion to Participate in The Citizens Life Sciences Conference
April 25, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025
April 24, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Report First Quarter 2025 Financial Results on May 6
April 23, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025
April 10, 2025
Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology and its Therapeutic Potential in Multiple Life-Threatening Diseases
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Appoints Robert E. Hoffman to Board of Directors
April 01, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference
March 24, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia
March 20, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Therapeutics Retail Bulls Charge In As Stock Notches Best Day In 3 Months On Impressive Q4
March 04, 2025
CEO Sheldon Koenig expects to drive further revenue gains and reach operating profitability through the expansion of its bempedoic acid products in the U.S. and Europe and global expansion into key...
Via
Stocktwits
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results
March 04, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 4, 2025
March 04, 2025
Via
Benzinga
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia
March 03, 2025
– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with a Profitable Transfer Price on Product Sales –
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
February 18, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 13, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Host Virtual Key Opinion Leader Event on Wednesday, January 22, 2025, at 11:30 a.m. ET.
January 09, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
January 02, 2025
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
December 18, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 13, 2024
Via
Benzinga
Esperion Announces $210 Million Convertible Debt Financing
December 13, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
December 12, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk
December 02, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
November 26, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
November 21, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
November 18, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 08, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.